Biosimilar program reshapes FDA’s objectivityFebruary 11, 2016Ankylosing spondylitisPsoriatic ArthritisRheumatoid ArthritisSpondyloarthropathiesBusiness of Medicine
House panel says Medicare biosimilar payment plan will stifle innovationFebruary 10, 2016Business of Medicine
Rituxan led Medicare part B drug spending in 2014February 1, 2016Rheumatoid ArthritisBusiness of Medicine
CMS releases applications, instructions for 2015 meaningful use hardship exemptionsJanuary 22, 2016Business of Medicine
Patient records requests: New regs clarify physician responsibilitiesJanuary 21, 2016Business of Medicine
DME: New prior authorization requirements could up the ‘hassle factor’January 19, 2016Business of Medicine
